According to uniQure's latest financial reports the company's current earnings (TTM) are -$0.31 B. In 2022 the company made an earning of -$0.13 B a decrease over its 2021 earnings that were of $0.33 B.The earnings displayed on this page is the company's Pretax Income.
Year | Earnings | Change |
---|---|---|
2023 (TTM) | -$0.31 B | 139.01% |
2022 | -$0.13 B | -138.54% |
2021 | $0.33 B | -335.29% |
2020 | -$0.15 B | 13.88% |
2019 | -$0.13 B | 49.51% |
2018 | -$83.08 M | 4.55% |
2017 | -$79.46 M | 12.65% |
2016 | -$70.54 M | -9.59% |
2015 | -$78.02 M | 66.95% |
2014 | -$46.74 M | 30.8% |
2013 | -$35.73 M |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
Amgen AMGN | $7.85 B | -2,662.33% | ๐บ๐ธ USA |
Sanofi SNY | $8.39 B | -2,838.59% | ๐ซ๐ท France |
Sangamo Therapeutics
SGMO | -$0.12 B | -61.18% | ๐บ๐ธ USA |
bluebird bio
BLUE | -$91.14 M | -70.27% | ๐บ๐ธ USA |
BioMarin Pharmaceutical BMRN | $0.18 B | -161.51% | ๐บ๐ธ USA |
Avidity Biosciences RNA | -$0.22 B | -30.77% | ๐บ๐ธ USA |